Baricitinib (Olumiant®) for moderate to severe atopic dermatitis. HTA ID: 20056

Assessment Status Rapid Review complete
HTA ID 20056
Drug Baricitinib
Brand Olumiant®
Indication Treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.
Assessment Process
Rapid review commissioned 14/12/2020
Rapid review completed 28/01/2021
Rapid review outcome A full HTA is not recommended. The NCPE recommends that baricitinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.